Want to see PETV full AI Analyst Report?
PETV Stock Chart & Stats
$1.12
$0.00(0.00%)
At close: 4:00 PM EST
$1.12
$0.00(0.00%)
Day’s Range― - ―
52-Week Range$0.60 - $1.69
Previous CloseN/A
Volume249.00
Average Volume (3M)21.60K
Market Cap
$28.81M
Enterprise Value$24.67
Total Cash (Recent Filing)$350.78K
Total Debt (Recent Filing)$376.16K
Price to Earnings (P/E)―
Beta0.09
Next Earnings
Aug 06, 2026EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.36
Shares Outstanding37,594,246
10 Day Avg. Volume14,407
30 Day Avg. Volume21,604
Financial Highlights & Ratios
PEG Ratio0.16
Price to Book (P/B)9.60
Price to Sales (P/S)18.49
P/FCF Ratio-3.45
Enterprise Value/Market Cap<0.01
Enterprise Value/Revenue<0.01
Enterprise Value/Gross Profit<0.01
Enterprise Value/Ebitda>-0.01
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
Health Canada Device RecognitionRegulatory recognition by Health Canada materially expands addressable market access and legitimizes Spryng for Canadian veterinarians. That durable market entry supports multi-year commercial rollouts into a market cited with mid-single-digit CAGR, improving long-term revenue opportunity and go-to-market credibility.
Exclusive AI Partnership & PetVivo.aiA decade-long exclusive AI licensing deal plus a scalable B2B SaaS product creates a structural, high-margin revenue stream. Beta metrics show large CAC reductions and targeted 80%–90% gross margins, implying durable customer economics, low incremental cost to scale, and potential data-driven monetization over years.
PBM Acquisition Expands Biomaterials IPAcquiring PBM adds proprietary piezoelectric biomaterials, broadening the product pipeline and IP estate. If closed, the deal can accelerate R&D, enable new device lines and licensing opportunities, and diversify applications across animal and potentially human health, strengthening long-term technology moat.
Bears Say
Persistent Cash BurnSustained negative operating and free cash flow erode liquidity and require repeated capital raises. Over a multi‑month horizon this constrains investment in commercialization, R&D and the PBM integration, raises financing and dilution risk, and limits the company’s ability to self-fund growth initiatives.
Large, Widening Net LossesSteep and growing net losses signal operating model is far from break-even. Persistent negative earnings reduce retained capital and equity cushions, increase dependence on external funding, and make multi‑period path to sustainable profitability uncertain absent material revenue scale or margin improvement.
Limited Liquidity RunwayA modest working capital balance leaves limited runway for commercialization, inventory builds, and completing the PBM acquisition which requires further equity financing. This structural liquidity constraint increases execution risk and likelihood of near-term fundraising that can dilute shareholders.
PetVivo Holdings News
PETV FAQ
What was PetVivo Holdings’s price range in the past 12 months?
PetVivo Holdings lowest stock price was $0.60 and its highest was $1.69 in the past 12 months.
What is PetVivo Holdings’s market cap?
PetVivo Holdings’s market cap is $28.81M.
When is PetVivo Holdings’s upcoming earnings report date?
PetVivo Holdings’s upcoming earnings report date is Aug 06, 2026 which is in 18 days.
How were PetVivo Holdings’s earnings last quarter?
PetVivo Holdings released its earnings results on Jun 29, 2026. The company reported -$0.088 earnings per share for the quarter, missing the consensus estimate of N/A by N/A.
Is PetVivo Holdings overvalued?
According to Wall Street analysts PetVivo Holdings’s price is currently Overvalued.
Does PetVivo Holdings pay dividends?
PetVivo Holdings does not currently pay dividends.
What is PetVivo Holdings’s EPS estimate?
PetVivo Holdings’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does PetVivo Holdings have?
PetVivo Holdings has 37,594,246 shares outstanding.
What happened to PetVivo Holdings’s price movement after its last earnings report?
PetVivo Holdings reported an EPS of -$0.088 in its last earnings report, missing expectations of N/A. Following the earnings report the stock price went down -4.545%.
Which hedge fund is a major shareholder of PetVivo Holdings?
Currently, no hedge funds are holding shares in PETV
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
PetVivo Holdings
PetVivo Holdings, Inc. operates as a biomedical technology firm, specializing in the invention, commercialization, and licensing of advanced medical devices and biomaterials intended to treat a variety of ailments and diseases affecting animals. Its flagship product is Spryng, an intra-articular injection administered by veterinarians to effectively alleviate lameness and joint conditions, such as osteoarthritis, in canines and equines. The company's development pipeline further includes seventeen therapeutic devices poised for both veterinary and human clinical applications. Founded in 2009, PetVivo Holdings, Inc. maintains its corporate headquarters in Minneapolis, Minnesota.
Technical Analysis
Ownership Overview
39.35% Insiders
0.34% Other Institutional Investors
60.31% Public Companies and
Individual Investors